Sarah Gooding
Overview
Explore the profile of Sarah Gooding including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
375
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Welsh F, Sundaravadanan S, Sethi P, Kazeroun M, Fichera A, Nadziruddin I, et al.
HPB (Oxford)
. 2025 Jan;
PMID: 39827007
Background: The optimal strategy for patients with colorectal liver metastases (CRLM) is unclear. The Precision1 prospective, observational trial assessed whether pre-operative functional imaging and whole genome sequencing (WGS), could enhance...
3.
Teoh P, Koh M, Mitsiades C, Gooding S, Chng W
Haematologica
. 2024 Nov;
PMID: 39569422
Acquired resistance to immunomodulatory drugs (IMiDs) remains a significant unmet need in the treatment landscape of multiple myeloma (MM). CRBN pathway-dependent mechanisms are known to be vital contributors to IMiD...
4.
Van Oekelen O, Amatangelo M, Guo M, Upadhyaya B, Cribbs A, Kelly G, et al.
Cell Rep Med
. 2024 May;
5(6):101584.
PMID: 38776911
Iberdomide is a potent cereblon E3 ligase modulator (CELMoD agent) with promising efficacy and safety as a monotherapy or in combination with other therapies in patients with relapsed/refractory multiple myeloma...
5.
Agarwal G, Moore S, Sadler R, Varghese S, Turner A, Chen L, et al.
Haematologica
. 2024 Jan;
109(6):1960-1965.
PMID: 38268439
No abstract available.
6.
Twumasi C, Moore S, Sadler R, Jeans S, Varghese S, Turner A, et al.
Eur J Haematol
. 2023 Dec;
112(4):547-553.
PMID: 38116695
Objective: To describe determinants of persisting humoral and cellular immune response to the second COVID-19 vaccination among patients with myeloma. Methods: This is a prospective, observational study utilising the RUDYstudy.org...
7.
Kurata K, James-Bott A, Tye M, Yamamoto L, Samur M, Tai Y, et al.
Blood Cancer J
. 2023 Feb;
13(1):24.
PMID: 36746923
No abstract available.
8.
Kurata K, James-Bott A, Tye M, Yamamoto L, Samur M, Tai Y, et al.
Blood Cancer J
. 2023 Jan;
13(1):12.
PMID: 36631435
Multiple myeloma (MM) is a plasma cell malignancy characterised by aberrant production of immunoglobulins requiring survival mechanisms to adapt to proteotoxic stress. We here show that glutamyl-prolyl-tRNA synthetase (GluProRS) inhibition...
9.
Agarwal G, Nador G, Varghese S, Getu H, Palmer C, Watson E, et al.
Cancers (Basel)
. 2023 Jan;
15(1).
PMID: 36612090
Novel biomarkers for tumour burden and bone disease are required to guide clinical management of plasma cell dyscrasias. Recently, bone turnover markers (BTMs) and Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) have...
10.
Chen L, Gooding S
Front Oncol
. 2022 Nov;
12:1038329.
PMID: 36439455
Resistance to immunomodulatory drugs (IMiDs) is a major cause of treatment failure, disease relapse and ultimately poorer outcomes in multiple myeloma (MM). In order to optimally deploy IMiDs and their...